Skip to main content
TIBET AIM PHARM. INC. logo

TIBET AIM PHARM. INC. — Investor Relations & Filings

Ticker · 002826 ISIN · CNE100002C39 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,084 across all filing types
Latest filing 2025-04-24 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002826

About TIBET AIM PHARM. INC.

https://www.emyy.cn

Tibet Aim Pharm. Inc. is a pharmaceutical enterprise focused on the research, development, production, and distribution of medicinal products. The company integrates traditional Tibetan medicine with modern pharmaceutical manufacturing processes to develop a diverse portfolio of treatments. Its core product range typically includes cardiovascular medications, digestive system therapies, and specialized herbal formulations derived from high-altitude botanical sources. Tibet Aim Pharm. Inc. emphasizes the modernization of traditional formulas through rigorous clinical testing and standardized production techniques. The company serves healthcare providers and patients by providing therapeutic solutions that bridge ancient medical knowledge with contemporary scientific standards.

Recent filings

Filing Released Lang Actions
2024年度独立董事述职报告-肖兴刚
Board/Management Information Classification · 95% confidence The document is titled as the "2024年度独立董事述职报告" which translates to "2024 Annual Independent Director's Work Report". It details the independent director's background, attendance at board and committee meetings, communication with auditors, supervision of company operations, and key focus areas during the year 2024. The content is a detailed report of the independent director's duties and activities over the year, including oversight of financial reports, internal controls, and governance matters. This type of document is a management or board-related report focusing on the independent director's role and responsibilities rather than a general annual report or audit report. It is not a simple announcement or certification but a substantive report on management/board activities. Therefore, the most appropriate classification is "Board/Management Information (MANG)" as it relates to board-level reporting and management oversight information.
2025-04-24 Chinese
2024年年度报告
Annual Report Classification · 100% confidence The document is titled as the "2024 Annual Report" of 西藏易明西雅医药科技股份有限公司 (Tibet Aim Pharm Inc.). It contains detailed sections typical of an annual report, including company overview, financial data, management discussion and analysis, governance, social responsibility, and financial statements. The document length is about 15,000 characters, indicating a full report rather than a brief announcement. It includes signed financial statements and an audit report, as well as comprehensive financial and operational data for the fiscal year 2024. The presence of detailed financial metrics, management analysis, and company information confirms this is the official yearly report covering company activity and full financial performance. FY 2024
2025-04-24 Chinese
2024年限制性股票激励计划预留授予激励对象名单（授予日）
Remuneration Information Classification · 95% confidence The document is a list of reserved grants of restricted stock incentive plan recipients for the year 2024 by the company 西藏易明西雅医药科技股份有限公司. It details the names, positions, and stock quantities allocated to management and core personnel. This is a disclosure related to stock-based compensation incentives, which typically falls under remuneration or incentive plan announcements. It is not a full annual report, audit report, earnings release, or other financial report. It is also not a proxy solicitation or voting result announcement. The document is short (724 characters) and contains specific details about stock incentives for management, which aligns with Remuneration Information filings. Therefore, the best fitting category is Remuneration Information (DEF 14A).
2025-04-24 Chinese
2024年年度财务报告
Annual Report Classification · 100% confidence The document is titled as the "2024 年度财务决算报告" which translates to "2024 Annual Financial Settlement Report". It contains detailed financial statements including balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the full fiscal year 2024. The document also includes an auditor's report with an unqualified opinion from a certified accounting firm, which is typical for an annual report. The length of the document (8533 characters) and the presence of comprehensive financial data and analysis confirm it is a full annual financial report rather than a brief announcement or certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2024
2025-04-24 Chinese
2024年度独立董事述职报告-冯岚
Board/Management Information Classification · 95% confidence The document is titled as the "2024年度独立董事述职报告" which translates to "2024 Annual Independent Director's Work Report." It details the independent director's duties, attendance at board and committee meetings, communication with auditors, supervision of company governance, and protection of shareholder interests during the 2024 fiscal year. It includes personal background, work performed, and evaluations related to governance and compliance. The content is a detailed report on the independent director's activities and oversight for the year, not an announcement or proxy solicitation. This fits the category of Board/Management Information (MANG), which covers announcements of changes or reports related to the company's board or senior management activities. It is not an Annual Report (10-K) or Audit Report (AR) because it focuses on the independent director's duties and governance role rather than full financial performance or audit results. The document length (4809 characters) and detailed content confirm it is a substantive report, not a brief announcement or certification. Therefore, the best classification is MANG with high confidence.
2025-04-24 Chinese
2024年度监事会工作报告
Management Reports Classification · 95% confidence The document is titled as the "2024年度监事会工作报告" which translates to "2024 Supervisory Board Work Report". It details the supervisory board's activities, including oversight of financial management, internal controls, audit reports, and company operations during the 2024 fiscal year. It includes references to audit reports, financial statements, internal control evaluations, and supervisory opinions on company governance and compliance. The document is a comprehensive report from the supervisory board summarizing their work and findings for the year 2024. It is not an announcement or a brief summary but a detailed report on supervisory activities and oversight. This fits the category of a Management Report (MDA), which includes management's detailed explanation of financial results, business trends, and outlook, as the supervisory board is part of the governance and management oversight structure. The document length is 3609 characters, which is relatively short but contains substantive content and detailed supervisory opinions, not just an announcement or certification. Therefore, the best classification is Management Reports (MDA).
2025-04-24 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.